1 / 14

Retinal Disease Unmet Need and Commercial Opportunity Assessment

Retinal Disease Unmet Need and Commercial Opportunity Assessment. A proposal for Alcon Laboratories February 15, 2011. Feb. 9, 2011. Table of Contents. Background and Objectives Our Approach, Methods and Deliverables Team, Timing & Fees IMS Consulting Qualifications Appendix: Bios.

zita
Download Presentation

Retinal Disease Unmet Need and Commercial Opportunity Assessment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Retinal Disease Unmet Need and Commercial Opportunity Assessment A proposal for Alcon Laboratories February 15, 2011 Feb. 9, 2011

  2. Table of Contents Background and Objectives Our Approach, Methods and Deliverables Team, Timing & Fees IMS Consulting Qualifications Appendix: Bios IMS / Alcon Retinal Disease Assessment

  3. Alcon seeks a comprehensive, objective view of the unmet needs and commercial opportunities across a broad array of eye-related diseases Background & Objectives Overall Project Goal Alcon is seeking a comprehensive understanding of the Global Retinal/Choroidal/Vitreal Disease market and pipeline to better inform their strategic direction Research Objectives • Identify unmet needs in the retinal, choroidal, and vitreal disease areas including: • Retinal and choroidal vascular diseases • Degenerative diseases of the retina • Retinal inflammatory diseases • Retinal detachment & vitreal diseases • Tumors of the retina & choroid • Inherited retinal diseases • Identify and assess the scientific and clinical relevance of therapies, surgical interventions, and diagnostics in development • Assess the likelihood of technical success and detail considerations that would impact the adoption of therapies into diagnosis and treatment algorithms • Provide epidemiologic forecasts of annualized prevalence, incidence, diagnosed and treated patients by disease type by country IMS / Alcon Retinal Disease Assessment

  4. At the highest level, retinal diseases can be grouped by etiology The diseases Alcon are interested in can potentially fall within ten treatment algorithms The manifestations and management of pathologic myopia and polypoidal choroidal vasculopathy resemble those of macular degeneration The various stages of diabetic retinopathy have well-delineated treatment paradigms that can be described in a single comprehensive decision tree Branch and central vein occlusion are separate diseases, but their management can be described within a single decision tree Adult (melanoma) and pediatric (retinoblastoma) ocular tumors are fundamentally different, but they could potentially be described as different branches of a tumor treatment algorithm Given the similarity of having an underlying genetic basis and current lack of effective treatments, the various inherited retinal diseases could potentially be combined into a single treatment flow diagram Background & Objectives Degenerative 1 Vascular 2 3 4 5 Inflammatory 6 Mechanical 7 8 Neoplastic 9 Hereditary 10 IMS / Alcon Retinal Disease Assessment

  5. IMS successfully supported Alcon in a very similar effort for the glaucoma franchise in 2009 / 2010 Background & Objectives IMS worked with the Alcon team over 2.5 months to develop an objective assessment of the glaucoma space The Alcon / IMS team collaborated throughout the project, with phased deliverables and checkpoints IMS brought to bear a broad team of both functional (Pricing, Reimbursement, Market Access, Strategy) and therapeutic expertise to maximize the insights to the Alcon team IMS / Alcon Retinal Disease Assessment

  6. Based on initial discussions and RFP, Alcon seeks objective views in three key areas Background & Objectives What strategic alternatives should Alcon consider to compete in the retinal/ choroidal/ vitreal disease marketplace? Unmet needs analysis:What are the unmet needs for patients? Clinical and technical assessment:What future treatment modalities hold the highest promise? Commercial assessment:What commercially viable opportunities exist? Key Questions: • What are the unmet medical needs of patients? • Of those unmet needs, would solutions / treatments of them present true clinical advances/ benefits? • What relevant therapies (pharma, device, surgical, diagnostics) are under development and do they represent significant treatment advancements? • What is the likelihood of technical/ clinical success of these different treatment pathways? • Based on EPI forecasts, what disease areas represent sizable market opportunities to pursue? • What approaches may represent commercially viable (reimbursable) advancements on current therapies? Supporting Information: • KOL perspectives on treatment evolution • Testing of treatment alternatives with a mix of specialist physicians • Literature and secondary market information research • Secondary research profiling competing treatment platforms • KOL and physician primary research (qual and quant) • IMS therapeutic area expertise and input • IMS, Alcon and third party epidemiological data and forecasts • Conversations with leading academics / epidemiologists focused on diseases of the eye • Literature and secondary research • IMS forecasting, EPI and pricing and market access functional expertise IMS / Alcon Retinal Disease Assessment

  7. Table of Contents Background and Objectives Our Approach, Methods and Deliverables Team, Timing & Fees IMS Consulting Qualifications Appendix: Bios IMS / Alcon Retinal Disease Assessment

  8. There are several important skills required to ensure success of this project IMS Consulting Qualifications IMS / Alcon Retinal Disease Assessment

  9. IMS Strategy & Portfolio Analysis We work at three levels of client problems, focusing to a varying extent on organic and/or externally-sourced options Consulting Expertise IMS Consulting Qualifications Organic Choices Externally-focused options Corporate Portfolio Business Model Design Strategic Footprint & Direction M&A Strategy Post Merger Portfolio Integration Asset Portfolio &Franchise Strategy Resource Allocation R&D Productivity Therapy Area Expansion Geographic Expansion Product Strategy & Valuation Development Strategy Market Assessment & Forecasting Product Licensing Deal valuation IMS / Alcon Retinal Disease Assessment

  10. Our consulting team excels at business intelligence, valuation, and strategy Assessing difficult-to-value assets with uncertain future prospects… molecules, brands, franchises, businesses, etc. Obtaining important business intelligence that will provide context for decision-making Helping organizations reach agreement on difficult choices involving many conflicting views…project teams, executive committees, boards of directors, etc. Managing decision processes that incorporate multiple different alternatives or options…strategies, investments, acquisitions, etc. Managing a portfolio brings these capabilities together: Gaining clarity on a complex mix of decisions Where there are many possible options, valuation is based on uncertain future prospects, and there are many conflicting views Consulting Expertise IMS Consulting Qualifications IMS / Alcon Retinal Disease Assessment

  11. IMS Consulting has deep expertise in the area of eye diseases and care Ophthalmic Experience IMS Consulting Qualifications Examples are illustrative, not exhaustive IMS / Alcon Retinal Disease Assessment

  12. IMS successfully supported Alcon in a very similar effort for the glaucoma franchise in 2009 / 2010 Experience with Alcon IMS Consulting Qualifications • IMS worked with the Alcon team over 2.5 months to develop an objective assessment of the glaucoma space • The Alcon / IMS team collaborated throughout the project, with phased deliverables and checkpoints • IMS brought to bear a broad team of both functional (Pricing, Reimbursement, Market Access, Strategy) and therapeutic expertise to maximize the insights to the Alcon team IMS / Alcon Retinal Disease Assessment

  13. IMS Management Consulting is the largest consulting firm dedicated to the life sciences industry Global Presence IMS Consulting Qualifications We have a presence in ~30 countries including the 11 scoped in this project IMS / Alcon Retinal Disease Assessment

  14. Our specialist consultancy business model provides depth in critical issue areas Functional Expertise IMS Consulting Qualifications Product and Portfolio Strategy Pricing and Market Access Commercial Effectiveness • Strategy & Portfolio Analysis • Forecasting & Valuation • Licensing & Acquisitions • Portfolio Management • Strategy • Competitive intelligence • Precision Sales Force TM • Promo.360 TM • Performance Mgt studies and dashboards • Primary market research • Learning solutions • Pricing and reimbursement • Health economics and outcomes research Core Offerings IMS / Alcon Retinal Disease Assessment

More Related